UT M.D. Anderson Cancer Center Lymphoma SPORE

UT M.D. 安德森癌症中心淋巴瘤孢子

• 批准号: 8120295
• 负责人: LARRY W KWAK
• 金额: $ 47.5万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8120295
• 关键词: UT; M.D.; Anderson; Cancer; Center

The University of Texas M. D. Anderson Cancer Center is proposing a Lymphoma Specialized Program of Research Excellence (SPORE). The primary goal of this Lymphoma SPORE is to improve the cure rate of lymphoma through innovative therapeutic strategies based on effective and focused translation of recent discoveries in lymphoma biology, immunology, and molecular genetics. The M. D. Anderson Lymphoma SPORE is a multidisciplinary collaborative effort between basic and translational scientists, clinical investigators, hematopathologists, and biostatisticians that is organized in 4 research projects and 4 core resources, as well as programs for developmental research and career development program. The research projects listed are designed to target specific areas important in lymphoma: Project 1 - Epigenetic-based therapy of Hodgkin lymphoma (Liu/Younes) Project 2 - Development of 8-chloro-adenosine therapy (Gandhi/McLaughlin) Project 3 - Targeting MDM2/P53 in ALL (Andreeff/O'Brien) Project 4 - Gene expression profiling and pathway targeted therapy in peripheral T-cell lymphoma (Chan/Vose) Core and other resources are the following: Core A - Administrative Core B - Biospecimen Core C - Clinical Research Core D - Biostatistics and Bioinformatics Development Research Program (DRP) and Career Development Program (CDP)

德克萨斯大学M. D.安德森癌症中心提出了一个淋巴瘤专业研究卓越计划（孢子）。该淋巴瘤孢子的主要目标是通过创新的治疗策略，基于淋巴瘤生物学，免疫学和分子遗传学的最新发现的有效和集中的翻译，提高淋巴瘤的治愈率。分枝D.安德森淋巴瘤孢子是基础和转化科学家，临床研究人员，血液病理学家和生物统计学家之间的多学科合作努力，组织在4个研究项目和4个核心资源，以及发展研究和职业发展计划的计划。 列出的研究项目旨在针对淋巴瘤中重要的特定领域： 项目1 -基于表观遗传学的霍奇金淋巴瘤治疗（Liu/Younes） 项目2 -开发8-氯腺苷疗法（Gandhi/McLaughlin） 项目3 -在ALL中靶向MDM 2/P53（Andreeff/奥布莱恩） 项目4 -外周T细胞淋巴瘤的基因表达谱和通路靶向治疗（Chan/Vose） 核心资源和其他资源如下： 核心A -行政 核心B -生物标本 核心C -临床研究 核心D -生物统计学和生物信息学 发展研究计划（DRP）和职业发展计划（CDP）

项目成果

Functional inhibition of BCL2 is needed to increase the susceptibility to apoptosis to SMO inhibitors in diffuse large B-cell lymphoma of germinal center subtype.

• DOI: 10.1007/s00277-013-1684-6
• 发表时间: 2013-06
• 期刊: ANNALS OF HEMATOLOGY
• 影响因子: 3.5
• 作者: Kunkalla, Kranthi;Liu, Yadong;Qu, Changju;Leventaki, Vasiliki;Agarwal, Nitin K.;Singh, Rajesh R.;Vega, Francisco
• 通讯作者: Vega, Francisco

Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorders.

• DOI: 10.1038/emm.2014.105
• 发表时间: 2015-01-23
• 期刊: EXPERIMENTAL AND MOLECULAR MEDICINE
• 影响因子: 12.8
• 作者: Cai, Qingqing;Chen, Kailin;Young, Ken H.
• 通讯作者: Young, Ken H.

Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries.

• DOI: 10.18632/oncotarget.3479
• 发表时间: 2015-03-20
• 期刊: Oncotarget
• 作者: Xu-Monette ZY;Tu M;Jabbar KJ;Cao X;Tzankov A;Visco C;Nagarajan L;Cai Q;Montes-Moreno S;An Y;Dybkaer K;Chiu A;Orazi A;Zu Y;Bhagat G;Richards KL;Hsi ED;Choi WW;van Krieken JH;Huh J;Ponzoni M;Ferreri AJ;Zhao X;Møller MB;Farnen JP;Winter JN;Piris MA;Miranda RN;Medeiros LJ;Young KH
• 通讯作者: Young KH

Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials.

• DOI: 10.1158/1078-0432.ccr-11-2018
• 发表时间: 2012-02-01
• 期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
• 作者: Berry DA;Herbst RS;Rubin EH
• 通讯作者: Rubin EH

Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.

产生一种新的治疗肽，该肽会耗尽肿瘤含量的小鼠中髓样衍生的抑制细胞。

• DOI: 10.1038/nm.3560
• 发表时间: 2014-06
• 期刊: Nature medicine
• 影响因子: 82.9